Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Vetter’s Development Service Doubles its Revenues and Grows its Capabilities

Published: Friday, September 28, 2012
Last Updated: Friday, September 28, 2012
Bookmark and Share
Ravensburg development labs add enhanced technologies.

Vetter reports that its Development Service doubled its revenues over the last five years, due to increased customer demand for support on complex biologics.

Vetter Development Service (VDS) supports products from preclinical development through Phase III and develops robust processes that enable a seamless transfer to Vetter Commercial Manufacturing.

Offering a continuum of service, the global VDS organization comprises more than 150 scientists, engineers and other personnel.

Vetter’s Chicago facility provides early-stage clinical production, featuring equipment optimized for small-batch manufacturing.

Ravensburg facilities support a range of development products through Phase III and feature sophisticated new technologies with enhanced analytical capabilities.

One-year anniversary: Chicago
Since the full operational launch of VDS Chicago, Vetter´s first U.S. facility, in October 2011, the site has contracted with a number of companies from around the globe, including Belgium, Israel and Korea, in addition to the United States.

Supporting preclinical through Phase II products, the site has already released customer batches for clinical trials.

Over the past few months, the Chicago site has expanded analytical and microbial testing; added 2,000 square feet of GMP storage; and built out its business office to accommodate more than 20 additional work spaces.

Future plans include adding a third cleanroom to the two existing ones, which will expand current operations and provide filling of pre-sterilized syringes.

New analytics: Ravensburg
As part of its continuous investment in its facilities, over the last year Vetter acquired sophisticated new technologies at its Ravensburg development labs that enable better control of syringe and cartridge siliconization; more-accurate detection of sub-visible particles in drug products; and a greater ability to simulate commercial-level processes in the VDS setting, for even smoother product transfer to commercial production.

Said Paul Nelles, Ph.D., Vice President of Vetter Development Service, “The growth of VDS demonstrates the increasing need for expert support in the development of complex compounds, to address a growing market. This rise in demand confirms our decision to expand Vetter Development Service to North America, as was urged by our U.S.-based customers.”

Upcoming conference participation
Vetter will exhibit its development service portfolio at:
• CPhI / iCSE, October 9 - 11, Madrid, Spain, booth 10E83
• AAPS Annual Meeting, October 14 - 18, Chicago, booth 5020
• PDA, The Universe of Pre-Filled Syringes & Injection Devices, October 15 - 17, Las Vegas, booth 207

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Vetter Announces Office Opening in Japan
Company’s second office in the region will strengthen customer relations and help develop new business among emerging and established Japanese companies.
Thursday, October 15, 2015
Vetter Embarks on a 300 Million Euro Investment Strategy
Company will invest for further development to its manufacturing sites and to make available additional manufacturing capacities.
Thursday, October 01, 2015
Vetter Development Service Chicago Completes Recent On-Site Expansion Activities
Continued demand and increased customer product transfers are generating a positive business outlook for the company’s early-stage development facility.
Thursday, June 11, 2015
Vetter Serializes the First Product for South Korea
CDMO produces clearly identifiable labelling for a top-ten pharmaceutical company.
Saturday, May 02, 2015
Vetter Appoints Oliver Albrecht as Managing Director
Role with company commenced on April 1, 2015.
Thursday, April 09, 2015
Vetter Continues to Expand Capacity
Structural work completed on Vetter’s new multi-functional building for its Development Service and information technology (IT).
Friday, January 30, 2015
Vetter Adds Flexible Serialization Service to its Portfolio
A new service allowing for the explicit identification of drug packaging.
Thursday, December 04, 2014
Vetter Announces Opening of Office to Support Growing Asian Healthcare Market
New Asia Pacific office will support customer relations and the development of new business.
Friday, November 21, 2014
Vetter Announces Personnel Changes in its Development Service Division
Clinical manufacturing services continue to attract new business.
Saturday, October 18, 2014
Vetter Continues to Strengthen its Market Position
Another positive year for the CDMO.
Wednesday, January 15, 2014
Vetter to Construct New Filling Lines to Expand Capacity
Responding to customer demand and company growth.
Thursday, October 10, 2013
Vetter’s New Commercial Filling Line Ready for cGMP Filling
Novel, high-tech line fully validated; first customer project underway.
Monday, April 08, 2013
Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013
Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013
Vetter Offers Answers for the Future at the Pharma Congress 2013
Experts from the CDMO to discuss the challenges and solutions facing the industry.
Tuesday, February 19, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos